We propose the following audit measures focusing on those guidelines supported by robust randomized evidence:
- The proportion of people with each grade 1 recommendation for use prescribed an SGLT 2 inhibitor (with exploration of reasons for non-use to direct quality improvement projects)
- The proportion of people prescribed an SGLT 2 inhibitor not on concomitant RAS blockade